Abstract: The present invention relates to soybean leaves or soybean stems having high isoflavone derivative content, and a method for preparing the same. Specifically, by finding that soybean leaves or soybean stems treated with ethylene and ethephon, i.e. a ethylene donor, show significantly increased isoflavone derivative content, the method for preparing the soybean leaves or soybean stems having high isoflavone derivative content and the soybean leaves or soybean stems having high isoflavone derivative content prepared by using the method can be useful as functional foods and medicinal materials for diseases due to estrogen imbalance and lack of the antioxidative activity.

Abstract: The present invention provides personal care compositions comprising a carrier and a mixture of essential oil components having specific levels of eucalyptol, terpene materials and auxiliary fragrance materials. The compositions herein gentle to skin and have a fragrance and activity similar if the composition were made using the pure extracted essential oil.

Abstract: The invention relates to the use of tomatoes for inhibition, amelioration or prevention of adipogenesis mediated diseases such as obesity, lipid storage disease and hyperlipemia. Provided is a tomato plant, fruit, fragment or extract thereof for use in a method for preventing weight gain, and/or inhibiting, preventing or ameliorating a disease condition associated with adipogenesis in a mammal, wherein the tomato is a ripening-impaired mutant tomato, such as a ripening inhibitor (rin), nonripening (nor), and/or never ripe (Nr) gene mutant tomato. Also provided are anti-adipogenic extracts and compositions comprising the extract.

Abstract: Multi-component formulations comprise methylsulfonylmethane, fructose 1,6-diphosphate, and just one of trehalose, green tea extract, ashwagandha, and rutin, or a combination thereof. Multi-component formulations can prevent, delay, or treat cognitive decline, Alzheimer's disease, and other dementias.

Abstract: The present invention relates generally to a composition comprising palm fruit juice for use in a method of preventing and inhibiting vision loss due to angiogenesis related diseases. The composition of the present invention aids to decrease in CNV size using confocal microscopy, in addition to reduction in macrophage infiltration using immune staining; decrease in VEGF-A-induced angiogenesis using established cornea pocket assay, inhibition of IKB-D phosphorylation in laser treated choroidal tissues and reduction in macrophage recruitment to CNV lesions.

Abstract: The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/or impairment, pain, and traumatic brain injury.

Abstract: This invention relates, in part, to methods and compositions that are useful for the treatment and/or prevention of various disorders, including radiation-related disorders, such as acute radiation syndrome.

Abstract: Methods and compositions are provided for the therapeutic use of Wnt proteins, for enhancing bone growth and regeneration, including repair following injury, osseointegration of implants, and the like. In some embodiments of the invention, the compositions are administered locally, e.g. by injection at the site of an injury. For certain conditions it is desirable to provide Wnt activity for short periods of time, and an effective dose will be administered over a defined, short period of time.

Abstract: The embodiments include methods of preventing or reducing the progression of prostate cancer in mammals susceptible to developing prostate cancer, and to methods of reducing the incidence of clinically detected prostate cancer, using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof.

Abstract: A method for treating a microbial infection in a subject includes administering to the subject a pharmaceutical composition which has a therapeutically effective amount of an antimicrobial peptide containing a derivative of P-113.

Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.

Abstract: The present invention relates to the boosting of Treg cells for the treatment of Alzheimer's disease and related disorders.

Abstract: The present invention provides a method of treatment for cancer in a subject comprising the administration of a prodrug, wherein the subject is colonised with an obligate anaerobic microorganism capable of expressing a polypeptide having nitroreductase activity, wherein the polypeptide exhibits preferential reduction of CB1954 to a 4-hydroxylamine (4HX) derivative instead of a 2-hydroxylamine derivative; and is capable of reducing CB1954 to the 4HX derivative with a Km of less than 30 micromolar. The present invention further provides an isolated polypeptide, nucleic acids encoding said polypeptide, vectors and host cells comprising said nucleic acids and vectors and uses of the above in treating solid tumours.

Abstract: The present invention relates to an injection composition comprising hyaluronidase for topical fat reduction. More particularly, the present invention relates to an injection composition comprising 300 IU to 600 IU of hyaluronidase and a local anesthetic, an antihistamine, a lipolysis stimulator and a collagen production stimulator. The present invention promotes the reduction of topical fat tissue, thereby improving obesity and helping weight loss and maintenance of body shape while preventing side effects or skin imbalance by the even removal of fat. Further, at the same time, the present invention can achieve a skin lifting effect where skin resilience is maintained by the stimulation of collagen production.

Abstract: The present disclosure provides a delivery system comprising (i) a physiologically acceptable carrier and (ii) a proteolytic enzyme or effector thereof for use in a method for relaxing fibers within a subject's oral cavity. In some embodiments, the relaxation is for use in tooth manipulation (particularly repositioning). In some embodiments, the method involves the use of the proteolytic enzyme or effector thereof at a concentration effective to cause relaxation of fibers between the tooth's alveolar bone and gingiva while maintaining integrity of the fibers surrounding the tooth. Also disclosed herein are methods for fiber relaxation and/or repositioning of tooth making use of the proteolytic enzyme or effector thereof.

Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.

Abstract: The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins; Antibodies induced or generated by the use of said malaria vaccines or said nucleic acid molecules encoding said proteins and/or fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Abstract: Provided are compositions and methods of selecting at least three fragments one each from three domains of the malarial CSP for generating antigen specific CD8 effector T cells and non-cross reacting neutralizing antibody immune responses to the malarial parasite, which when administered prevent an infection of a human being when bitten by a malaria infected mosquito. The composition and method comprises priming an individual by administering a mixture of one or more adenoviral expression vectors encoding one or more fusion proteins, which comprises the malarial CSP antigen fragments linked to the extracellular domain of the CD40 ligand. The adenoviral expression vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing selected malarial sporozoite CSP antigen fragments linked to the CD40 ligand to block the attachment to or infection of the human liver cell(s) by the malarial sporozoite.

Abstract: This disclosure describes, generally, compositions and methods related to thermostable vaccine formulations, their storage, and their use. Generally, the thermostable vaccine formulations can be in the form of a dry powder. The dry powder formulations can increase the length of time that the vaccine remains viable under non-refrigerated, ambient temperature conditions.

Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).

Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

Abstract: The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting with fibronectin, laminin and the complement system.

Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.

Abstract: A method of producing attenuated cells for a mammalian vaccine comprising killing or attenuating the cells with a high energy, low heat UV light.

Abstract: This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.

Abstract: The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium and which comprises a concentration of the metal(s) of at least 60 mg/ml. The solution further comprises at least one compound selected from the group comprising iodine, potassium iodide, sodium iodide, iron, iron chloride, zinc oxide, manganese sulphate, sodium selenite, copper carbonate, sodium carbonate, anhydrous disodium EDTA and sodium hydroxide. The trace element solution is prepared by a method consisting essentially of the steps of preparing a MnCO3 mixture in a container; adding an EDTA/NaOH mixture to the container and subsequently adding at least one metal compound; and adding Na2SeO3 to the container to obtain the trace element solution. The method also comprises the step of adding CrCl3.6H2O to the trace element solution.

Abstract: A topical pharmaceutical or cosmetic composition for treatment of irritation of mucous cells such as mucosal cells of the eye, nose, and vagina is disclosed. The composition comprises an aqueous solution of at least one polyol selected from the group consisting of xylitol, myoinositol and mannitol and at least one substance selected from the group consisting of glycerol and urea. The composition contains less than 0.01% inorganic salt and is free of any oil-in-water or wax-in-water emulsion. In particularly preferred embodiments, the composition comprises an aqueous solution containing 1.5-5% (w/v) xylitol and 0.9-2.0% (w/v) glycerol.

Abstract: An iron-based composition is described. The composition can be used in conditions of total or relative iron deficiency. In particular, a solid composition is described, preferably in the form of powder or granules, for use in the treatment of disorders or diseases related to or derived from an iron deficiency. The composition is suitable for pediatric subjects, adolescents, athletes, men, women, pregnant women and elderly. Finally, a process for preparing the solid composition is also described.

Abstract: Disclosed herein are drug delivery molecules that comprise a ligand that targets a cell surface molecule; a membrane penetration domain; and a payload binding domain; and pharmaceutical compositions comprising the same. Also disclosed are methods of treating cancer, inhibiting the progression of cancer, preventing cancer metastasis, and delivering a therapeutic compound to the brain in a subject in need thereof, the methods comprising identifying a subject in need thereof; providing a composition comprising the drug delivery molecule as disclosed herein; and administering an effective amount of the composition to the subject.

Abstract: Vascular endothelial growth factor VEGF-sequestering hydrogel microspheres that have been prepared to selectively bind VEGF from blood products are disclosed herein. In one particular embodiment, the microspheres bind VEGF as part of an intra-operative process such that the growth factor can be removed from the blood products before the products are used in a clinical procedure.

Abstract: Nanoparticles (and optionally a cargo such as a drug) can be delivered to cells by attaching just a single dendritic peptide to the nanoparticle. The dendritic peptide includes a polyhisitidine motif and a hinge and a spacer connecting the polyhistidine to a lysine-based dendritic wedge displaying at least two copies of a cell-penetrating peptide motif.

Abstract: The method for remote, non-invasive in vivo control of the activation of light-sensitive bioactive molecules for the purpose of research or therapy is based on delivering to the required site of the body of nanoparticles along with said light-sensitive bioactive molecules. Nanoparticles' core is made from scintillator material that absorbs X-ray and in response emits visible light; they have biocompatible protective coating and surface targeting agents enabling accumulation at the required site(s) within the body. Irradiation of the site with the highly penetrable X-rays causes nanoparticles to emit visible light which will activate light-sensitive bioactive molecule(s) within this site inducing sought therapeutic effect.

Abstract: 18F labeled IDO1 imaging constructs are constructed for positron emission tomography (PET). Synthetic methodology involves the coupling of a 1-fluoro-2-halo-4-aminobenzene and a 4-mino-N-hydroxy-1,2,5-oxadiazole-3-carboximidoyl chloride wherein at least one of the coupled compounds comprises an 18F. The 18F labeled IDO1 imaging constructs are useful for imaging cancer cells in a patient.

Abstract: A metal mesh has a plurality of through-holes. A photosensitive organic material is attached to at least part of the metal mesh. The metal mesh is sterilized and/or cleaned. A determination of whether or not the sterilization and/or cleaning has been successful is made by analyzing the photosensitive organic material attached to the metal mesh.

Abstract: Techniques for automatically eradicating microorganisms (e.g., germs, bacteria, and/or viruses) from appliance handles using ultraviolet (UV) light are provided. In one aspect, a system for eradicating biological contaminants from a handle on an appliance door is provided. The system includes a UV light emitter for producing UV disinfecting light during a cleaning cycle; and a waveguide coating on the handle, coupled to the UV light emitter, for propagating the UV disinfecting light over a surface of the handle. The system can also include a control module for controlling the UV light emitter; and at least one sensor for providing data to the control module as to when to initiate or halt a cleaning cycle. A method for eradicating biological contaminants from a handle on an appliance door using the present system is also provided.

Abstract: A system capable of detecting and/or sterilizing surface(s) of an object using ultraviolet radiation is provided. The system can include a disinfection chamber and/or handheld ultraviolet unit, which includes ultraviolet sources for inducing fluorescence in a contaminant and/or sterilizing a surface of an object. The object can comprise a protective suit, which is worn by a user and also can include ultraviolet sources for disinfecting air prior to the air entering the protective suit. The system can be implemented as a multi-tiered system for protecting the user and others from exposure to the contaminant and sterilizing the protective suit after exposure to an environment including the contaminant.

Abstract: Introducing ultraviolet (UV) light to interior portions of footwear alters the environment inside a shoe or other footwear to destroy microorganisms or inhibit their growth. Visible light can also be used to prevent further microorganism growth. Introducing forced air flow through the footwear removes dampness in and thereby deodorizes the footwear. A preferred embodiment comprises an adjustable shoe tree equipped with a UV germicidal light source and electronic safeguards that prevent appreciable leakage of UV radiation outside the shoe.

Abstract: The disclosed invention relates to a two-part liquid composition for cleaning and disinfecting a substrate, comprising: (A) a disinfectant medium comprising peracetic acid; and (B) a supplemental medium comprising a non-enzymatic cleaner, a corrosion inhibitor, and a chelator. The supplemental medium (B) may further comprise an enzymatic cleaner, a surfactant, a buffer, a pH modifier, or a mixture of two or more thereof. The substrate may be a medical device, for example, an endoscope.

Abstract: New forms of self-sterilizing and antiseptic surfaces are provided. In some embodiments, a handled surface or GUI comprises internal hardware performing a heavy rinse of the handled surface triggered by an end-of-use function. In other embodiments, pressure on a handled surface instead causes the surface to uniformly exude water and other antiseptic compositions from a refillable source.

Abstract: A sterilization method for a medical instrument housed in a housing container includes a temperature-increasing step of housing the housing container in the autoclave and introducing high pressure steam into the autoclave to increase a temperature within the autoclave to a prescribed temperature, a cover sheet being thermally bonded to a peripheral wall portion of the container main body; a sterilizing step of holding the temperature within the autoclave at the prescribed temperature for a prescribed time to sterilize a medical instrument; and a cooling step of reducing the temperature within the autoclave. In the temperature-increasing step, the sterilizing step, and the cooling step, compressed gas is introduced into the autoclave under a steam atmosphere obtained by the introduction of the high pressure steam to increase a current pressure in the autoclave to higher than or equal to a pressure in the housing container and inhibit the cover sheet from peeling from the peripheral wall portion.

Abstract: A cleanroom autoclave system including a reusable autoclave breather bag and a reusable fill line hopper cover. The autoclave bag is formed from a launderable abrasion resistant inner fabric layer and a launderable polyester outer fabric layer, and has a zipper closure. The hopper cover is formed from a circular bonnet and an open tubular skirt formed from a launderable polyester fabric, and includes an elastic portion and snaps to secure the hopper cover.

Abstract: A volatile substance delivery system includes a volatile substance container to contain a volatile substance, an optional absorbent and collapsible element disposed within the container to reduce presence of undesired air during manufacture of the device, an outlet to deliver a volume of the volatile substance from the volatile substance container to an ambient environment, and a manual screw pump to reduce volume (or sometimes, just increase pressure) within the volatile substance container and promote the delivery of the volatile substance from the volatile substance container.

Abstract: A sanitary article includes an absorbent pad including an upper sheet layer, a lower sheet layer, and a pulp-and-SAP powder layer combination. The powder layer combination is constituted by alternate layers of pulverized pulp and superabsorbent polymer (SAP) powder. A method for making the sanitary article is also disclosed.

Abstract: A wound dressing composition comprising a non-viable cell lysate or releasate derived from a hepatocyte cell or an inflammatory cell such as a macrophage. Also provided are wound dressings comprising such compositions, methods of making such compositions, and the use of such compositions for the treatment of wounds.

Abstract: Provided is a biodegradable water absorbent having high gel strength and exhibiting an excellent absorption factor and excellent liquid passage rate through a gel. A water absorbent comprising a cross-linked naturally derived polymer and a clay mineral, the water absorbent being characterized in that the cross-linked naturally derived polymer and the clay mineral form particles, the clay mineral is present in the interior of the particles, and the clay mineral content constitutes 10-100 parts by mass (when dry) relative to 100 parts by mass (when dry) of the cross-linked naturally derived polymer. It is possible to produce this water absorbent by preparing a starting material fluid in which the naturally derived polymer is dissolved and the clay mineral is dispersed, adding a cross-linking agent to the starting material fluid, and cross-linking the naturally derived polymer.

Abstract: The invention is directed to a bone void filler comprising a scaffold or matrix. The scaffold or matrix may include a porous inorganic matrix component. The bone void filler may include a cellular component containing cells, some of which are capable of making extracellular matrix resembling native bone tissue. The bone void filler may include an organic matrix, such as, an organic biopolymer that aids in cell retention and renders the scaffold or matrix moldable. The bone void filler may include growth factors and/or cytokines. The bone void filler may include a clotting agent.

Abstract: A method for treating a valve of a heart of a subject is provided. The method includes inserting a needle into the heart, and, using the needle, injecting a soft-tissue-filling material into an annulus of the valve. Other embodiments are also described.

Abstract: The present invention establishes a new standard for investigative studies of patient-specific, genetic cardiac diseases at a functional, tissue level by creating a novel platform for the study of cardiac related diseases, including cardiac conduction dysfunction, arrhythmias and depressed contractility for example. Provided herein are novel compositions of human engineered heart slices (EHS) formed from thin slices of decellularized cardiac tissue. Also included are compositions comprising a hybrid of decellularized tissue and organotypic organ slice technology. Intact mammalian hearts are precision cut to obtain thin slices in a range of thicknesses, decellularized, and seeded with various mammalian cells which can be from a variety of sources. Methods of investigation of many diseases and methods of use of these compositions for screening compounds for therapeutic purposes are also provided.

Abstract: A polytetrafluoroethylene tube is provided and has a thickness of 0.1 mm or less, a tensile elongation at break of 350% or more, and a melting energy of 0.6 J/g or more which is calculated from an endothermic peak at 370° C.±5° C. in a procedure of increasing a temperature in differential scanning calorimetry (DSC).

Abstract: Catechol-bearing polycarbonates (catechol polymers) were prepared comprising i) a catechol repeat unit comprising a side chain catechol group, ii) a cationic repeat unit comprising a side chain cationic group selected from the group consisting of quaternary amine groups, quaternary phosphine groups, and combinations thereof, and iii) a PEG repeat unit comprising a side chain poly(ethylene oxide) group having a degree of polymerization of about 5 to about 30. The catechol polymers form antimicrobial and antifouling films on a variety of substrate surfaces, in particular silicone rubber.